Hepatic Steatosis Clinical Trial
— SHAHOfficial title:
Hepatic Steatosis and Pituitary Gland Failure, Evaluation by NMR Imaging
Verified date | February 2024 |
Source | Centre Hospitalier Universitaire Dijon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.
Status | Completed |
Enrollment | 21 |
Est. completion date | October 10, 2015 |
Est. primary completion date | October 10, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who have provided consent - Patients over 18 years - Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary. Exclusion Criteria: - Persons without national health insurance - Pacemaker (Contra-Indication for MRI) - Alcohol consumption greater than 4 glasses a day - Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden - Presence of metallic implants (Contra-Indication for MRI) - Claustrophobia - Adult under guardianship - Pregnant or breast-feeding women - Patients with a liver disease other than non-alcoholic steatosis |
Country | Name | City | State |
---|---|---|---|
France | CHU Dijon Bourgogne | Dijon |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Dijon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of liver fat mass by Magnetic Resonance Imaging (MRI) | Measured at Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
Completed |
NCT03717935 -
Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS
|
N/A | |
Active, not recruiting |
NCT02493153 -
Hepatic Steatosis After Cholecystectomy
|
N/A | |
Active, not recruiting |
NCT05654051 -
The SLIM LIVER Study
|
Phase 2 | |
Completed |
NCT03334214 -
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT05599945 -
First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
|
Phase 1 | |
Enrolling by invitation |
NCT02816814 -
Lacto-ovo-vegetarian Diet Riched in Omega-3 Fatty Acids in Menopausal Women
|
N/A | |
Active, not recruiting |
NCT03587727 -
Hepatic Mitochondrial Function in Youth
|
||
Not yet recruiting |
NCT06363617 -
Implementation of the Fatty Liver Index in Primary Care
|
N/A | |
Not yet recruiting |
NCT05935826 -
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
|
N/A | |
Not yet recruiting |
NCT06394206 -
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
|
N/A | |
Recruiting |
NCT03142698 -
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
|
N/A | |
Completed |
NCT00480922 -
Effects of a Low Glycemic Load Diet on Fatty Liver in Children
|
N/A | |
Not yet recruiting |
NCT05871749 -
Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B
|
||
Recruiting |
NCT05897073 -
Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity
|
N/A | |
Completed |
NCT03961516 -
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
|
||
Completed |
NCT04180631 -
Quantitative US for Hepatic Steatosis
|
N/A | |
Terminated |
NCT00845845 -
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 |